Skip to content
AnalystLens

Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2024

Filing Date
Filed July 23, 2024
Period End
June 30, 2024
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Dec ’17Dec ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Material agreement8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jun ’26Jun ’26

Summary

Summary of the 10-Q filed July 23, 2024. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. reported strong second-quarter 2024 results in its Form 10-Q.

Net revenue rose 14.6% to $528.1 milliona for the three months ended June 30, 2024, from $460.9 million a year earlier, and rose 16.1% to $1,039.1 million for the six months. The filing attributes the growth to Metabolic, Oncology and Other therapeutic areas. Income from operations was $105.2 million for the quarter versus $78.4 million, and net income was $88.4 million versus $61.1 million.

Diluted EPS was $2.75b compared with $1.93. For the six months, net income was $190.9 million and diluted EPS was $5.96, versus $134.0 million and $4.20 in the prior-year period. Liquidity strengthened considerably.

Cash and cash equivalents increased to $510.9 millionc from $245.4 million at December 31, 2023, and net cash provided by operating activities was $269.1 million for the six months, compared with $162.6 million. Advanced billings rose to $638.4 million from $559.9 million. The company reported no indebtedness at June 30, 2024, and its credit facility line was reduced to up to $10.0 million.

Shareholders' equity increased to $763.6 million, and the accumulated deficit narrowed to $30.8 milliond from $221.6 million. Forward indicators were mixed. Backlog increased $353.0 million, or 13.7%, to $2,924.9 million, and the company expects approximately $1,575.0 million to $1,595.0 million of that backlog to convert to net revenue over the next twelve months.

Net new business awards were $551.0 million in the quarter, compared with $574.8 million a year earlier, and $1,166.5 million for the six months, compared with $1,130.6 million. The company made no share repurchases in the first half of 2024 and had $308.8 million of remaining authorization under its repurchase program.

Key Highlights

  1. Q2 2024 net revenue of $528.1 million, up 14.6% from $460.9 million; six-month revenue of $1,039.1 million, up 16.1%.
  2. Q2 2024 net income of $88.4 million (diluted EPS $2.75) versus $61.1 million (diluted EPS $1.93) in Q2 2023.
  3. Cash and cash equivalents of $510.9 million at June 30, 2024, up from $245.4 million at December 31, 2023.
  4. Six-month net cash provided by operating activities of $269.1 million, compared with $162.6 million in the prior-year period.
  5. Backlog of $2,924.9 million at June 30, 2024, up $353.0 million or 13.7% year over year.
  6. No indebtedness at June 30, 2024; the revolving credit facility was reduced to up to $10.0 million under Amendment No. 6.
  7. No share repurchases in the first six months of 2024; $308.8 million remains under the repurchase authorization.

Financial Statements

Q2 FY2024 against Q2 FY2023

Line itemQ2 FY2024Q2 FY2023Change
Revenue$528.10M$460.87M+14.6%
SG&A Expenses$41.45M$39.40M+5.2%
Operating Expenses$422.95M$382.48M+10.6%
Operating Income$105.15M$78.39M+34.1%
Net Income$88.35M$61.07M+44.7%
EPS (Basic)$2.85$2.00+42.5%
EPS (Diluted)$2.75$1.93+42.5%
Shares Outstanding (Basic)30.99M30.54M+1.5%
Shares Outstanding (Diluted)32.09M31.57M+1.6%

Frequently Asked Questions

  1. What drove the revenue growth in the quarter?

    The filing states that the increase was broad based but primarily driven by growth within the Metabolic, Oncology and Other therapeutic areas. Reimbursed out-of-pocket expenses, which can fluctuate significantly by period, rose $24.7 million in the quarter and were a major component of higher total direct costs.

  2. How strong is the company's liquidity position?

    Cash and cash equivalents were $510.9 million at June 30, 2024, up from $245.4 million at December 31, 2023. The company had no indebtedness at quarter end, and $10.0 million was available for borrowing under its Credit Facility. Approximately $20.6 million of cash was held by foreign subsidiaries.

  3. What does the backlog and new business activity indicate about future revenue?

    Backlog was $2,924.9 million, up 13.7% from $2,571.9 million a year earlier, and about $1,575.0 million to $1,595.0 million is expected to convert to net revenue over the next twelve months. Net new business awards were $551.0 million in the quarter, down from $574.8 million a year earlier, though six-month awards rose to $1,166.5 million from $1,130.6 million. The filing cautions that backlog and award metrics may not reliably indicate future period revenue.

  4. Did the company return capital to shareholders in 2024?

    No share repurchases were executed during the three and six months ended June 30, 2024, compared with 126,281 shares for $23.9 million in the second quarter of 2023 and 781,068 shares for $144.0 million in the first half of 2023. Remaining authorization under the $500.0 million program was $308.8 million.

  5. What drove the change in the effective tax rate?

    The effective tax rate was 20.0% for the three months ended June 30, 2024, compared with 19.4% a year earlier, and 14.5% for the six months compared with 17.2%. The filing attributes the six-month decrease primarily to higher excess tax benefits from share-based compensation and tax benefits related to Foreign Derived Intangible Income.